Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: A phase I study

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 28, Issue 6, 2005, Pages 570-575

  Iannitti, David ^a   Dipetrillo, Tom ^a   Akerman, Paul ^a   Barnett, John Mark ^a   Maia Acuna, Christine ^a   Cruff, Dennis ^a   Miner, Tom ^a   Martel, Diane ^a   Cioffi, William ^a   Remis, Melissa ^a   Kennedy, Teresa ^a   Safran, Howard ^a,b  

^a Brown University Oncology Group   (United States)

^b MIRIAM HOSPITAL   (United States)

Author keywords

Erlotinib; Gemcitabine; Paclitaxel; Pancreatic cancer; Radiotherapy

Indexed keywords

ATROPINE; DEXAMETHASONE; DIPHENHYDRAMINE; DIPHENOXYLATE; ERLOTINIB; GEMCITABINE; LOPERAMIDE; PACLITAXEL; RANITIDINE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DISEASE COURSE; FLATULENCE; HUMAN; HYPERSENSITIVITY; INFECTION; MAINTENANCE THERAPY; MAXIMUM TOLERATED DOSE; NEPHROTOXICITY; NEUTROPENIA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; RASH; THROMBOCYTOPENIA; THROMBOSIS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HUMANS; LIFE TABLES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PACLITAXEL; PANCREATECTOMY; PANCREATIC NEOPLASMS; QUINAZOLINES; RADIOTHERAPY, CONFORMAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 29044433659     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000184682.51193.00     Document Type: Article

References (22)

1. Willett CG, Safran H, Abrams RA, et al. Clinical research in pancreatic cancer: The Radiation Therapy Oncology Group (RTOG) Trials. Int J Radiat Oncol Biol Phys. 2003;56(4 suppl):31-37.
2. Huang SM, Harari PM. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs. 1999;17:259-269.
3. Grunwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst. 2003;95:851-67.
4. Moore MJ, Goldstin D, Hamm J, et al. Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. Proc ASCO Gastrointestinal Cancers Symposium 2005 (Abstract 77).
5. Chinnaiyan S, Huang S, Armstrong E, et al, Radiosensitization following EGFR signaling inhibition by erlotinib (Tarceva). Int J Rad Onc Biol Phys. 2003;57(suppl 1):S294.
6. Song J, Chen Changhu C, et al. Emerging role of EGFR-targeted therapies and radiation in head and neck cancer. Oncology. 2004;18:1757-1765.
7. Rich T, Harris J, Abrams R, et al. Phase II study of external irradiation and weekly paclitaxel for nonmetasatic, unresectable pancreatic cancer. Am J Clin Oncol. 2004;27:51-56.
8. Safran H, Moore T, Iannitti D, et al. Paclitaxel and concurrent radiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2001;49:1275-1279.
9. Safran H, DiPetrillo T, Iannitti D, et al. Gemcitabine, paclitaxel and radiation for locally advanced pancreatic cancer: a phase I trial. Int J Rad Onc Biol Phys. 2002;54:137-141.
10. Mendelsohn J, Baird A, Fan Z, et al. Growth factors and their receptors in epithelial malignancies. In: Mendelsohn J, Howley PM, Israel MA, Liotta LA, eds. The Molecular Basis of Cancer. Philadelphia, PA: W.B. Saunders Company, 2001:137-144.
11. Seymour LK. Epidermal growth factor receptor as a target: recent developments in the search for effective new anti-cancer agents. Curr Drug Targets. 2001;2:117-133.
12. Resnick M, Cohen-Uram M, Iannitti DS, et al. Expression of key signaling molecules in resected pancreatic cancer. Proc Am Soc Clin Oncol. 2004;23:874 (Abstract 9679).
13. Korc M, Chandrasekar B, Yamanaka Y, et al. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with conccomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest. 1992;90:1352-1360.
14. Abbruzzese JL, Rosenberg A, Xiong Q, et al. Phase II study of antiepidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol. 2001;20:130a (Abstract 518).
15. Harari P, Huang SM. Combining EGFR inhibitors with radiation or chemotherapy. Will preclinical studies predict clinical results. Int J Rad Oncol Biol Phy. 2004;58:976-983.
16. Bonner JA, Harari PM, Giralt J, et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a Phase III study of high dose radiation therapy with or without cetuximab. Proc Am Soc Clin Oncol. 2004;23 (Abstract 5507).
17. Aguiar D, Aguiar J, Bohn U. Alternating weekly administration of paclitaxel and gemcitabine: a phase II study in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2005;55:152-158.
18. Besalga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol. 2005;23:2445-2459.
19. Shepherd FA, Pereira J, Ciuleanu TE, et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. Proc Am Soc Clin Oncol. 2004;23 (Abstract 7022).
20. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-2139.
21. Besalga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of BD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol. 2002;20:4292-4302.
22. Hidalgo M, Siu LL, Neumunaitis J, et al. Phase I and pharmacologic study of OSI-774, and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 2001;19:3267-3279.